In what appears to be the first case to consider the issue, an Eastern District of Missouri court recently rejected the argument that the Supreme Court's Loper Bright Enterprises v. Raimondo1decision overruling Chevron deference undermines the basis for express preemption in medical device cases. Express preemption can be an effective defense in products cases involving medical devices.
Articles by Bryce Cooper
EDNY Allows Expert's Use Of ChatGPT To Confirm Alternative Design In Product Liability Lawsuit
The U.S. District Court for the Eastern District of New York recently allowed an expert's use of ChatGPT to confirm a proposed alternative design in a product liability lawsuit, denying the defendant's motion to exclude the expert testimony for failing the reliability requirement of Federal Rule of Evidence (FRE) 702.1 The plaintiff brought a lawsuit against Harbor Freight Tools USA, Inc., alleging that an axe he purchased from the defendant was defectively designed because the head of the...
Supreme Court Has A Chance To (Re-)Clarify Albrecht Impossibility Preemption Test
A cert petition filed earlier in March in the long-running In re Fosamax (Alendronate Sodium) Products Liability Litigation gives the Supreme Court a chance to clarify—for the second time—the Third Circuit's restrictive application of the impossibility preemption defense. Readers of this blog are likely familiar with impossibility preemption.
A Natural Solution: Court Dumps Microplastic Suit For Lack Of Scientific Evidence
The U.S. District Court for the Northern District of Illinois recently dismissed a putative class action complaint alleging the term "natural" on Fiji Water bottle labels is false and misleading due to alleged microplastics contained in the water, because the plaintiffs failed to provide specific evidence to plausibly establish such contamination.1 The plaintiffs brought a putative class action against The Wonderful Company LLC (TWC), a distributor and seller of Fiji Water, claiming, among...
The Growing Challenges To Drug Cos.' Preemption Defense
Law360 (August 26, 2020, 5:20 PM EDT) -- In the wake of the U.S. Supreme Court's decisions in Wyeth v. Levine[1] and Merck Sharp & Dohme Corp. v. Albrecht,[2] drug manufacturers face challenges in establishing a preemption defense when they receive "newly acquired information" about a drug's side effects without clear evidence that the U.S. Food and Drug Administration would have rejected a label change adding a warning of the risk of harm.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Bryce
Contact Bryce, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack